BCAS2
breast carcinoma amplified sequence 2
BCAS2; breast carcinoma amplified sequence 2; pre-mRNA-splicing factor SPF27; DAM1; Snt309; SPF27; DNA amplified in mammary carcinoma 1 protein; Spliceosome associated protein SPF 27; Breast carcinoma-amplified sequence 2; MGC7712; Pre mRNA splicing factor SPF27; SPF27_HUMAN; Spliceosome associated protein amplified in breast cancer; Spliceosome-associated protein SPF 27; OTTHUMP00000013668; spliceosome associated protein, amplified in breast cancer;
BCR
breakpoint cluster region
BCR; breakpoint cluster region; BCR1, D22S11; breakpoint cluster region protein; ALL; CML; D22S662; PHL; renal carcinoma antigen NY-REN-26; BCR1; D22S11; FLJ16453;
BRCA1
breast cancer 1, early onset
BRCA1; breast cancer 1, early onset; breast cancer type 1 susceptibility protein; BRCA1/BRCA2 containing complex; subunit 1; BRCC1; PPP1R53; protein phosphatase 1; regulatory subunit 53; RNF53; RING finger protein 53; BRCA1/BRCA2-containing complex, subunit 1; protein phosphatase 1, regulatory subunit 53; breast and ovarian cancer susceptibility protein 1; breast and ovarian cancer sususceptibility protein 1; IRIS; PSCP; BRCAI; PNCA4; BROVCA1;
DTNBP1
dystrobrevin binding protein 1
DTNBP1; dystrobrevin binding protein 1; sdy; Bloc1s8; AW048963; dysbindin; 5430437B18Rik; dysbindin; sandy; dysbindin-1; BLOC-1 subunit 8; HPS7 protein homolog; dystrobrevin-binding protein 1; hermansky-Pudlak syndrome 7 protein homolog; biogenesis of lysosome-related organelles complex 1 subunit 8;
SNCG
synuclein, gamma (breast cancer-specific protein 1)
SNCG; synuclein, gamma (breast cancer-specific protein 1); SR; BCSG1; gamma-synuclein; persyn; synoretin; breast cancer-specific gene 1 protein;
SSX4
synovial sarcoma, X breakpoint 4
SSX4; synovial sarcoma, X breakpoint 4; protein SSX4; CT5.4; MGC12411; Synovial sarcoma X breakpoint 4; OTTHUMP00000024292; OTTHUMP00000216158; cancer/testis antigen 5.4; SSX4B;
VAMP1
vesicle-associated membrane protein 1 (synaptobrevin 1)
VAMP1; vesicle-associated membrane protein 1 (synaptobrevin 1); SYB1; vesicle-associated membrane protein 1; VAMP 1; synaptobrevin 1; synaptobrevin-1; VAMP-1; DKFZp686H12131;
VAMP8
vesicle-associated membrane protein 8 (endobrevin)
VAMP8; vesicle-associated membrane protein 8 (endobrevin); vesicle-associated membrane protein 8; EDB; Endobrevin; VAMP 8; VAMP-8; VAMP8_HUMAN; Vesicle associated membrane protein 8;
XRCC5
X-ray repair complementing defective repair in Chinese hamster cells 5 (double-strand-break rejoining)
XRCC5; X-ray repair complementing defective repair in Chinese hamster cells 5 (double-strand-break rejoining); X ray repair complementing defective repair in Chinese hamster cells 5 (double strand break rejoining; Ku autoantigen, 80kD); X-ray repair cross-complementing protein 5; KARP 1; Ku autoantigen; 80kDa; KU80; Ku86; KUB2; TLAA; CTC85; CTCBF; nuclear factor IV; Ku autoantigen, 80kDa; DNA repair protein XRCC5; thyroid-lupus autoantigen; 86 kDa subunit of Ku antigen; lupus Ku autoantigen protein p86; Ku86 autoantigen related protein 1; CTC box-binding factor 85 kDa subunit; ATP-dependent DNA helicase 2 subunit 2; ATP-dependent DNA helicase II 80 kDa subunit; NFIV; KARP1; KARP-1; FLJ39089;
BCAR1
breast cancer anti-estrogen resistance 1
BCAR1; breast cancer anti-estrogen resistance 1; CAS; CAS1; CASS1; CRKAS; P130Cas; breast cancer anti-estrogen resistance protein 1; Crk-associated substrate p130Cas; Cas scaffolding protein family member 1;
BCAR3
breast cancer anti-estrogen resistance 3
BCAR3; breast cancer anti-estrogen resistance 3; breast cancer anti-estrogen resistance protein 3; NSP2; SH2D3B; BCAR 3; Novel SH2 containing protein 2; SH2 domain containing protein 3B; Breast cancer anti estrogen resistance 3; Breast cancer anti estrogen resistance protein 3; Breast cancer antiestrogen resistance 3; dJ1033H22.2; dJ1033H22.2 breast cancer anti estrogen resistance 3; dJ1033H22.2 breast cancer antiestrogen resistance 3; KIAA0554; NSP 2; SH2 containing protein Nsp2; OTTHUMP00000011959; OTTHUMP00000011960; OTTHUMP00000011961; OTTHUMP00000011962; novel SH2-containing protein 2; SH2 domain-containing protein 3B; dJ1033H22.2 (breast cancer anti-estrogen resistance 3);
BCAS1
breast carcinoma amplified sequence 1
BCAS1; breast carcinoma amplified sequence 1; breast carcinoma-amplified sequence 1; AIBC1; NABC1; novel amplified in breast cancer 1; amplified and overexpressed in breast cancer;
BRMS1
breast cancer metastasis suppressor 1
BRMS1; breast cancer metastasis suppressor 1; breast cancer metastasis-suppressor 1; DKFZP564A063; AV003220; AW554636; MGC95128; OTTHUMP00000235056; OTTHUMP00000235057; OTTHUMP00000235060; OTTHUMP00000235062;
EPSTI1
epithelial stromal interaction 1 (breast)
EPSTI1; epithelial stromal interaction 1 (breast); epithelial-stromal interaction protein 1; BRESI1; epithelial stromal interaction protein 1; MGC29634;
EWSR1
Ewing sarcoma breakpoint region 1
EWSR1; Ewing sarcoma breakpoint region 1; RNA-binding protein EWS; EWS; Ewings sarcoma EWS-Fli1 (type 1) oncogene; bK984G1.4;
JTB
jumping translocation breakpoint
JTB; jumping translocation breakpoint; protein JTB; hJT; prostate androgen regulated gene; HJTB; HSPC222; JTB_HUMAN; Jumping translocation breakpoint protein; OTTHUMP00000034759; PAR; PAR protein; Prostate androgen regulated protein; Prostate androgen-regulated protein;
SSX1
synovial sarcoma, X breakpoint 1
SSX1; synovial sarcoma, X breakpoint 1; protein SSX1; cancer/testis antigen family 5; member 1; CT5.1; X breakpoint 1; Cancer/testis antigen 5.1; Cancer/testis antigen family 5 member 1; MGC150425; MGC5162; sarcoma, synovial, X chromosome related 1; SSRC; SSX1_HUMAN; Synovial sarcoma; cancer/testis antigen family 5, member 1; sarcoma, synovial, X-chromosome-related 1;
SSX2
synovial sarcoma, X breakpoint 2
SSX2; synovial sarcoma, X breakpoint 2; SSX; protein SSX2; cancer/testis antigen family 5; member 2a; CT5.2a; HD21; HOM MEL 40; MGC3884; MGC15364; MGC119055; sarcoma; synovial; X chromosome related 2; synovial sarcoma; X breakpoint 2; isoform b; X breakpo;
DTNA
dystrobrevin, alpha
DTNA; dystrobrevin, alpha; dystrobrevin alpha; D18S892E; DRP3; DTN; DTN 1; DTN 2; DTN 3; dystrophin related protein 3; Alpha-dystrobrevin; DTN-A; DTNA_HUMAN; Dystrophin-related protein 3; FLJ96209; LVNC1; OTTHUMP00000163151; OTTHUMP00000163152; OTTHUMP00000163153; OTTHUMP00000163154; OTTHUMP00000163155; OTTHUMP00000245175; OTTHUMP00000245176; OTTHUMP00000245177; OTTHUMP00000245178;
BRCA2
breast cancer 2, early onset
BRCA2; breast cancer 2, early onset; FACD, FANCD, FANCD1, Fanconi anemia, complementation group D1; breast cancer type 2 susceptibility protein; BRCA1/BRCA2 containing complex; subunit 2; BRCC2; FAD; FAD1; fanconi anemia group D1 protein; breast cancer 2;
DTNB
dystrobrevin, beta
DTNB; dystrobrevin, beta; dystrobrevin beta; Beta dystrobrevin; Beta-dystrobrevin; DTN B; DTN-B; DTNB_HUMAN;
SSX3
synovial sarcoma, X breakpoint 3
SSX3; synovial sarcoma, X breakpoint 3; protein SSX3; CT5.3; MGC119054; Cancer/testis antigen 5.3; MGC14495; SSX3_HUMAN; synovial sarcoma, X breakpoint 3, isoform a;
BCAS3
breast carcinoma amplified sequence 3
BCAS3; breast carcinoma amplified sequence 3; breast carcinoma-amplified sequence 3; FLJ20128; 1500019F07Rik; 2610028P08Rik; AU021018; BC028339; BCAS3_HUMAN; GAOB1; K20D4; MAAB; Maab1 protein; MGC4973; rudhira; protein Maab1; BCAS4/BCAS3 fusion; metastasis associated antigen of breast cancer; breast carcinoma amplified sequence 4/3 fusion protein;
BCAS4
breast carcinoma amplified sequence 4
BCAS4; breast carcinoma amplified sequence 4; breast carcinoma-amplified sequence 4; CNOL; FLJ20495; BCAS4/BCAS3 fusion; breast carcinoma amplified sequence 4/3 fusion protein;
BRE
brain and reproductive organ-expressed (TNFRSF1A modulator)
BRE; brain and reproductive organ-expressed (TNFRSF1A modulator); BRCA1-A complex subunit BRE; BRCA1/BRCA2 containing complex; subunit 4; BRCC4; BRCC45; BRCA1/BRCA2-containing complex subunit 45; BRCA1/BRCA2-containing complex, subunit 4; brain and reprod;
ARFGEF2
ADP-ribosylation factor guanine nucleotide-exchange factor 2 (brefeldin A-inhibited)
ARFGEF2; ADP-ribosylation factor guanine nucleotide-exchange factor 2 (brefeldin A-inhibited); brefeldin A-inhibited guanine nucleotide-exchange protein 2; BIG2; Brefeldin A inhibited guanine nucleotide exchange protein 2; brefeldin A-inhibited GEP 2; PVN;
BRMS1L
breast cancer metastasis-suppressor 1-like
BRMS1L; breast cancer metastasis-suppressor 1-like; breast cancer metastasis suppressor 1 , BRMS1; breast cancer metastasis-suppressor 1-like protein; FLJ39177; MGC11296; breast cancer metastasis suppressor 1 like; BRM1L_HUMAN; BRMS1 homolog protein p40; BRMS1 like protein p40; BRMS1-homolog protein p40; BRMS1-like protein p40; BRMS1;
ARFGEF1
ADP-ribosylation factor guanine nucleotide-exchange factor 1 (brefeldin A-inhibited)
ARFGEF1; ADP-ribosylation factor guanine nucleotide-exchange factor 1 (brefeldin A-inhibited); brefeldin A-inhibited guanine nucleotide-exchange protein 1; ARFGEP1; BIG1; DKFZP434L057; p200; ADPribosylation factor guanine nucleotide exchange factor 1(brefeldin A inhibited); Brefeldin A inhibited GEP 1; Brefeldin A inhibited guanine nucleotide exchange protein 1; p200 ARF GEP1; p200 ARF guanine nucleotide exchange factor; OTTHUMP00000227052; OTTHUMP00000227095;
BCAN
brevican
BCAN; brevican; brevican core protein; BEHAB; brevican proteoglycan; chondroitin sulfate proteoglycan 7; CSPG7; MGC13038; Brain enriched hyaluronan binding protein; Brevican core protein isoform 1; Brevican core protein isoform 2; Chondroitin sulfate proteoglycan BEHAB; brain-enriched hyaluronan-binding protein;
GBF1
golgi brefeldin A resistant guanine nucleotide exchange factor 1
GBF1; golgi brefeldin A resistant guanine nucleotide exchange factor 1; Golgi-specific brefeldin A-resistance guanine nucleotide exchange factor 1; BFA-resistant GEF 1; ARF1GEF; KIAA0248; golgi-specific brefeldin A resistance factor 1; FLJ21500; MGC134877; MGC134878; OTTHUMP00000020365;
NBPF7
neuroblastoma breakpoint family, member 7
NBPF7; neuroblastoma breakpoint family, member 7; putative neuroblastoma breakpoint family member 7; LOC343505; NBPF 7;
NBPF8
neuroblastoma breakpoint family, member 8
NBPF8; neuroblastoma breakpoint family, member 8; hypothetical protein LOC728841; Neuroblastoma breakpoint family member 8; NBPF11; NBPF21;
PBOV1
prostate and breast cancer overexpressed 1
PBOV1; prostate and breast cancer overexpressed 1; prostate and breast cancer overexpressed gene 1 protein; UC28; UROC28; PBOV 1; dJ171N11.2;
SSX5
synovial sarcoma, X breakpoint 5
SSX5; synovial sarcoma, X breakpoint 5; protein SSX5; SSX5_HUMAN;
SSX2IP
synovial sarcoma, X breakpoint 2 interacting protein
SSX2IP; synovial sarcoma, X breakpoint 2 interacting protein; afadin- and alpha-actinin-binding protein; SSX2-interacting protein; afadin DIL domain-interacting protein; ADIP; FLJ10848; KIAA0923; MGC75026;
SSX4B
synovial sarcoma, X breakpoint 4B
SSX4B; synovial sarcoma, X breakpoint 4B; protein SSX4; OTTHUMT00000056510; Cancer/testis antigen 5.4; CT5.4; MGC119056; MGC12411; MGC169015; MGC169016; SSX4; SSX4A; Synovial sarcoma X breakpoint 4; Synovial sarcoma X breakpoint 4B;
Enbrel
Enbrel
Enbrel; Etanercept; CD120b; p75; p80 TNF-alpha receptor; TNF-R2; Tumor necrosis factor receptor 2; Tumor necrosis factor receptor superfamily member 1B precursor; Tumor necrosis factor receptor type II;
DBNDD1
dysbindin (dystrobrevin binding protein 1) domain containing 1
DBNDD1;dysbindin (dystrobrevin binding protein 1) domain containing 1;28455;ENSG00000003249;16q24.3;MGC3101, FLJ12582;dysbindin domain-containing protein 1;dysbindin domain-containing protein 1;
DBNDD2
dysbindin (dystrobrevin binding protein 1) domain containing 2
DBNDD2;dysbindin (dystrobrevin binding protein 1) domain containing 2;15881;ENSG00000244274;CK1BP;HSMNP1;C20orf35;20q13.12;dysbindin domain-containing protein 2;dysbindin domain-containing protein 2;casein kinase-1 binding protein;SCF apoptosis response protein 1;
ST18
suppression of tumorigenicity 18 (breast carcinoma) (zinc finger protein)
ST18;suppression of tumorigenicity 18 (breast carcinoma) (zinc finger protein);18695;ENSG00000147488;ZNF387;8q11.23;KIAA0535;suppression of tumorigenicity 18 protein;suppression of tumorigenicity 18 protein;zinc finger protein 387;
Tcl1
T cell lymphoma breakpoint 1
TCL1;T cell lymphoma breakpoint 1;ENSMUSG00000041359;Tcl1a;12 E;12 52.0 cM;T-cell leukemia/lymphoma protein 1A;T-cell leukemia/lymphoma protein 1A;TCL-1;oncogene TCL1;oncogene TCL-1;protein p14 TCL1;T-cell lymphoma breakpoint 1;
An Approved Malarial Drug is Promising for Preventing and Stopping Breast Cancer
Explore New Aspects from Old ItemsChloroquine During a clinical trial, researchers of Mason Center unexpectedly found a malarial drugChloroquine can stop the precursor cells of breast cancer, which brings hope and new thoughts for patients and doctors. Thus they launch a PINC (Preventing Invasiv...
Cleveland Clinic Published Its Selection of Top Three “Groundbreaking” Pharmaceutics
As usual, Cleveland Clinic will pick out some groundbreaking pharmaceutics that may make big difference for healthcare industry in their late development stages. This year who will be picked by Cleveland? According to internal news, Gilead's sofosbuvir, Novartis heart drugs serelaxin as well as Phar...
